Comparing predictors of conversion and decline in mild cognitive impairment
Abstract
A variety of measurements have been individually linked to decline in mild cognitive impairment (MCI), but the identification of optimal markers for predicting disease progression remains unresolved. The goal of this study was to evaluate the prognostic ability of genetic, CSF, neuroimaging, and cognitive measurements obtained in the same participants.
APOE epsilon4 allele frequency, CSF proteins (Abeta(1-42), total tau, hyperphosphorylated tau [p-tau(181p)]), glucose metabolism (FDG-PET), hippocampal volume, and episodic memory performance were evaluated at baseline in patients with amnestic MCI (n = 85), using data from a large multisite study (Alzheimer's Disease Neuroimaging Initiative). Patients were classified as normal or abnormal on each predictor variable based on externally derived cutoffs, and then variables were evaluated as predictors of subsequent conversion to Alzheimer disease (AD) and cognitive decline (Alzheimer's Disease Assessment Scale-Cognitive Subscale) during a variable follow-up period (1.9 +/- 0.4 years).
Citation impact
- FWCI
- 32.89
- Percentile
- 100%
- References
- 41
Authors
12Topics & keywords
- Episodic memory
- Cognitive decline
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's disease
- Internal medicine
- Neuroimaging
- Cognition
- Psychology
- Good health and well-being
Funding
- DWDonald W. Reynolds Foundation
- LLLarry L. Hillblom Foundation
- AAmgen
- BSBristol-Myers SquibbAwards: U01 AG024904, AG024904
- ELEli Lilly and CompanyAwards: U01 AG024904, AG024904
- PPfizerAwards: AG024904, U01 AG024904
- AAstraZeneca
- GGlaxoSmithKline
- BIBaxter International
- BBBen B. and Iris M. Margolis Foundation
- UOUniversity of PennsylvaniaAward: P50 NS053488
- ADAlzheimer's Disease Neuroimaging InitiativeAwards: AG024904, U01-AG024904, U01 AG024904
- TPTakeda Pharmaceuticals U.S.A.
- UOUniversity of Alabama at Birmingham
- UOUniversity of Alabama
- MGMyriad Genetics
- UOUniversity of Oxford
- EElanAward: U01 AG024904
- EEisaiAwards: U01 AG024904, AG024904
- NINational Institutes of HealthAwards: NINDS P50 NS053488-02, AG024904, AG10483, P50 NS053488, EB00768, NIA UO1 AG029213-01, U01 AG024904, R01 AG11378, NS053488, T32 NS07222, AG11378, AG 17586, NIA PO1 AG 17586-10, U01-AG024904
- GGenentechAwards: AG024904, U01 AG024904
- ARAvid Radiopharmaceuticals
- NINational Institute on AgingAwards: U01 AG024904, U01 AG10483, 10124, AG 16574, U01 AG 06786, AG031581, 17586, AG 06786, R01 AG11378, R01 AG031581, AG10483, AG024904, AG11378, AG 17586, U01-AG024904, R01AG029672, P50 AG 16574
- NINational Institute of Neurological Disorders and StrokeAwards: NS053488, T32 NS07222, P50 NS053488